声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。2月23日,诺和诺德宣布CagriSema对比替尔泊肽的减重III期REDEFINE 4研究未达到主要终点。受此消息影响,诺和诺德股价大跌15%。CagriSema为诺和诺德开发的一款复方药物,包含长效胰淀素(amylin)类似物Cagrilintide...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。2月23日,诺和诺德宣布CagriSema对比替尔泊肽的减重III期REDEFINE 4研究未达到主要终点。受此消息影响,诺和诺德股价大跌15%。CagriSema为诺和诺德开发的一款复方药物,包含长效胰淀素(amylin)类似物Cagrilintide...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.